United States General Accounting Office. Off-label drugs reimbursement policies constrain physicians in their choice of cancer therapies (report GAO/PEMD-91-14). September1991. Washington DC. Available at: http://archive.gao.gov/d18t9/144933.pdf. Last accessed October 18 2012.
AbernathyAPBalkEHammondJM. Compendia for coverage of off-label uses of drugs and biologics in an anticancer chemotherapeutic regimen. AHRQ Technology Assessment. Published May72007. Available at: http://www.cms.gov/medicare-coverage-database/details/technology-assessments-details.aspx?TAId=46&bc=BAAgAAAAAAAA&. Last accessed October 13 2012.
PeppercornJBursteinHMillerFG. Self-reported practices and attitudes of US oncologists regarding off-protocol therapy. J Clin Oncol2008;26:5994–6000.
Medicare. Compendia as Authoritative Sources for Use in the Determination of a ‘Medically Accepted Indication’ of Drugs and Biological Used Off-Label in an Anti-cancer Chemotherapeutic Regimen. MLN Matters. Number MM6191. Published November252008. Available at: http://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/downloads/MM6191.pdf. Last accessed October 13 2012.